XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.2

Notes to the Consolidated Statements of Operations (Tables)

6 Months Ended

Jun. 30, 2023

Notes to the Consolidated Statements of Operations

Schedule of revenue from contract with customers recognized

​

​	​	​	​	​	​	​	​	​
​		Three months ended June 30,			​	Six months ended June 30,
​	​	2022		2023		2022		2023
​	​	EUR k	​	EUR k	​	EUR k	​	EUR k
Belgium	​	​	​	​	​	​	​	​
GSK	​	19,295	​	6,283	​	43,041	​	12,756
Switzerland			​	​			​	​
CRISPR		406	​	844		586	​	1,053
Netherlands	​	​	​	​	​	​	​	​
Genmab	​	445	​	452	​	892	​	899
Total		20,146	​	7,579		44,519	​	14,708

Summary of upfront payments and related revenues recognized

​

​	​	​	​	​	​	​
​	​	​	​	Upfront and	​	Upfront and
​	​	​	​	milestones payments included	​	milestones payments included
​	​	​	​	in contract	​	in contract
​		Upfront and milestone		liabilities at		liabilities at
Customer	​	payments	​	December 31, 2022	​	June 30, 2023
​	​	​	​	(EUR k)	​	(EUR k)
GSK		EUR 205,000k (EUR 10,000k milestone payment included)		102,804		95,307
CRISPR		USD 3,000k (EUR 2,524k)*		929		775
Genmab		USD 10,000k (EUR 8,937k)*		3,575		2,681
Total		​		107,308		98,763

* Translated at the currency exchange rate prevailing on the transaction date.

​

​	​	​	​	​	​	​	​	​
​		Revenue recognized from
​	​	upfront and milestones payments
​	​	for three months ended			​	for six months ended
​	​	June 30,			​	June 30,
Customer	​	2022		2023		2022		2023
​		(EUR k)		(EUR k)		(EUR k)		(EUR k)
GSK		13,051		3,873		30,769		7,496
CRISPR		77		77		155		155
Genmab		447		447		894		894
Total		13,575		4,397		31,818		8,545

Schedule of contract balances

​

​	​	​	​	​
​		December 31,		June 30,
​	​	2022	​	2023
​	​	EUR k	​	EUR k
Trade receivables		6,295		6,443
Contract assets		2,707		119
Contract liabilities		107,308		98,763

Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses

The cost of sales consists of the following:

​

​	​	​	​	​	​	​	​	​
​		Three months ended June 30,			​	Six months ended June 30,
​	​	2022		2023		2022		2023
​	​	EUR k	​	EUR k	​	EUR k	​	EUR k
Personnel		(5,933)	​	(9,371)	​	(13,869)	​	(17,559)
Materials		(14,055)	​	(8,096)	​	(36,883)	​	(12,630)
Third-party services		(18,552)	​	(6,386)	​	(19,516)	​	(11,839)
Maintenance and lease		(919)	​	(534)	​	(1,150)	​	(1,115)
Amortization and depreciation		(3,158)	​	(1,049)	​	(8,326)	​	(2,219)
Other		(64)	​	(418)	​	(169)	​	(1,127)
Total		(42,681)	​	(25,854)	​	(79,913)	​	(46,489)

Selling and distribution expenses consist of the following:

​

​	​	​	​	​	​	​	​	​
​		Three months ended June 30,			​	Six months ended June 30,
​	​	2022		2023		2022		2023
​	​	EUR k	​	EUR k	​	EUR k	​	EUR k
Personnel		(363)	​	(1,314)	​	(560)	​	(2,030)
Amortization and depreciation		(16)	​	(6)	​	(32)	​	(6)
Other		(169)	​	(88)	​	(227)	​	(196)
Total		(548)	​	(1,408)	​	(819)	​	(2,232)

R&D expenses consists of the following:

​

​	​	​	​	​	​	​	​	​
​		Three months ended June 30,				Six months ended June 30,
​	​	2022		2023		2022		2023
​	​	EUR k	​	EUR k		EUR k	​	EUR k
Materials		(6,131)	​	(5,728)	​	(23,419)	​	(9,217)
Personnel		(7,795)	​	(12,533)	​	(14,849)	​	(23,570)
Amortization and depreciation		(1,106)	​	(1,783)	​	(2,119)	​	(3,508)
Patents and fees to register a legal right		502	​	(1,191)	​	(1,354)	​	(2,048)
Third-party services		4,252	​	(7,081)	​	21,053	​	(11,773)
Maintenance and lease		(428)	​	(1,827)	​	(464)	​	(3,593)
Other		(929)	​	(727)	​	(1,270)	​	(1,410)
Total		(11,635)	​	(30,868)	​	(22,422)	​	(55,118)

General and administrative expenses consist of the following:

​

​	​	​	​	​	​	​	​	​
​	​	Three months ended June 30,			​	Six months ended June 30,
​	​	2022		2023		2022		2023
​		EUR k		EUR k	​	EUR k	​	EUR k
Personnel		(9,190)	​	(6,644)	​	(18,971)	​	(15,742)
Maintenance and lease		(1,404)	​	(1,614)	​	(2,704)	​	(2,915)
Third-party services		(7,514)	​	(5,871)	​	(12,796)	​	(12,873)
Legal and other professional services		(2,995)	​	(4,446)	​	(5,320)	​	(6,074)
Amortization and depreciation		(3,152)	​	(2,965)	​	(6,091)	​	(6,071)
Other		(2,857)	​	(705)	​	(5,796)	​	(1,857)
Total		(27,112)	​	(22,245)	​	(51,678)	​	(45,532)

Schedule of other operating income

​

​	​	​	​	​	​	​	​	​
​	​	Three months ended June 30,				Six months ended June 30,
​	​	2022		2023		2022		2023
​		EUR k		EUR k		EUR k	​	EUR k
Compensation for CMO/Material transfer	​	949	​	259	​	33,961	​	1,803
Reimbursement Claim	​	610	​	—	​	610	​	—
Sale of equipment	​	—	​	176	​	310	​	484
Grants and other cost reimbursements from government agencies and similar bodies	​	35	​	237	​	104	​	239
Other		177	​	770	​	222	​	922
Total		1,771	​	1,442	​	35,207	​	3,448

X

- References

No definition available.

+ Details

Name:	cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract
Namespace Prefix:	cvac_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Disclosure of detailed information about upfront payments and related revenues recognized.

+ References

No definition available.

+ Details

Name:	cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory
Namespace Prefix:	cvac_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2022-03-24
-Paragraph 114
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of expenses by nature. [Refer: Expenses, by nature]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 10
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_DisclosureOfExpensesByNatureExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of other operating income. [Refer: Other operating income (expense)]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 10
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2022-03-24
-Paragraph 118
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration